OncoSec Medical Inc (ONCS) to Post Q3 2019 Earnings of ($0.14) Per Share, Piper Jaffray Companies Forecasts

Share on StockTwits

OncoSec Medical Inc (NASDAQ:ONCS) – Stock analysts at Piper Jaffray Companies upped their Q3 2019 earnings per share (EPS) estimates for OncoSec Medical in a report issued on Monday, March 11th. Piper Jaffray Companies analyst E. Tenthoff now expects that the biotechnology company will earn ($0.14) per share for the quarter, up from their previous forecast of ($0.18). Piper Jaffray Companies also issued estimates for OncoSec Medical’s Q4 2019 earnings at ($0.15) EPS, FY2019 earnings at ($0.56) EPS, Q1 2020 earnings at ($0.14) EPS, Q2 2020 earnings at ($0.16) EPS, Q3 2020 earnings at ($0.17) EPS, Q4 2020 earnings at ($0.18) EPS and FY2020 earnings at ($0.65) EPS.

Several other research firms have also weighed in on ONCS. Maxim Group set a $5.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a research note on Thursday, November 29th. Zacks Investment Research raised OncoSec Medical from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. OncoSec Medical currently has a consensus rating of “Buy” and an average price target of $3.13.

ONCS opened at $0.53 on Thursday. OncoSec Medical has a fifty-two week low of $0.42 and a fifty-two week high of $2.21.

OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Friday, December 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.06.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Moloney Securities Asset Management LLC boosted its stake in shares of OncoSec Medical by 117.4% during the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 27,000 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of OncoSec Medical by 484.1% in the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock worth $64,000 after buying an additional 83,150 shares during the period. Northern Trust Corp boosted its position in shares of OncoSec Medical by 33.6% in the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after buying an additional 28,914 shares during the period. Geode Capital Management LLC boosted its position in shares of OncoSec Medical by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after buying an additional 163,405 shares during the period. Finally, BlackRock Inc. boosted its position in shares of OncoSec Medical by 98.2% in the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock worth $311,000 after buying an additional 240,843 shares during the period. 6.41% of the stock is owned by institutional investors and hedge funds.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Featured Article: The mechanics of the bid-ask spread in trading

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.